Go Pro
→ Why Trump really wants Greenland (From Porter & Company) (Ad)tc pixel
NASDAQ:HUMAW

Humacyte 8/17/2026 Earnings Report

Humacyte logo
$0.0081 +0.00 (+1.25%)
As of 09:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Profile

Humacyte EPS Results

Actual EPS
N/A
Consensus EPS
-$0.10
Beat/Miss
N/A
One Year Ago EPS
N/A

Humacyte Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.12 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Humacyte Announcement Details

Quarter
Date
8/17/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Humacyte Earnings Headlines

Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026
August 7 at 6:52 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/humacyte-to-announce-2026-second-quarter-financial-results-and-provide-business-update-on-august-12-2026-1036428363
Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual ...
June 15, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/humacyte-s-bioengineered-blood-vessel-outperforms-the-standard-of-care-for-women-on-dialysis-in-phase-3-results-presented-at-the-society-for-vascular-surgery-vascular-annual-meeting-1036249157
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel
August 10 at 1:00 AM  |  Porter & Company (Ad)
Biggest stock movers: ORCL, HUMA, and more
June 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4602464-biggest-stock-movers-orcl-huma-and-more
Humacyte prices $50M public offering of common stock at $1.05/share
June 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/humacyte-prices-50m-public-offering-of-common-stock-at-1-05-share/ar-AA25m1jH
HUMA stock plunges after-hours on proposed share offering even as dialysis data impresses
June 10, 2026  |  msn.comhttps://www.msn.com/en-in/health/other/huma-stock-plunges-after-hours-on-proposed-share-offering-even-as-dialysis-data-impresses/ar-AA25kRdW
See More Humacyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Humacyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Humacyte and other key companies, straight to your email.

About Humacyte

Humacyte (NASDAQ:HUMAW) (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe. The company’s research collaborations include partnerships with academic institutions and pharmaceutical companies to explore the broader application of its technology in cardiovascular disease. Humacyte operates a state-of-the-art manufacturing facility in North Carolina, enabling scalable production and rigorous quality control under current good manufacturing practices (cGMP).

Under the leadership of a management team with extensive experience in regenerative medicine and biomanufacturing, Humacyte is focused on obtaining regulatory approvals and expanding access to its HAV products globally. As it progresses through pivotal clinical studies, the company aims to address significant unmet needs in vascular surgery and end-stage renal disease, offering patients a novel alternative to synthetic grafts and allografts.

View Humacyte Profile
Earnings Tools